What is UBS's price target for RPRX?

UBS's latest stated price target for Royalty Pharma plc (RPRX) is $49, from its action on Jan 30, 2026.

What is UBS's rating on RPRX?

UBS rates RPRX Buy, a bullish rating, as of Jan 30, 2026.

When did UBS last change its view on RPRX?

On Jan 30, 2026, UBS upgrades to Buy from Neutral, price target $49.

UBS RPRX price target and rating history

UBS rates Royalty Pharma plc (RPRX) Buy with a $49 price target, as of its latest action on Jan 30, 2026. It has published 3 rating actions on RPRX since June 2022, including 1 upgrade and 1 downgrade.

Current rating: Buy
Price target: $49
Median target, all firms: Too few
Actions on RPRX: 3

UBS price target on RPRX

UBS price target on RPRX, each point a stated target, June 2022 to January 2026.

Every UBS rating on RPRX

Jan 30, 2026
UpgradeUBS upgrades to Buy from Neutral, price target $49
Jun 3, 2024
DowngradeUBS downgrades to Neutral from Buy, price target $28
Jun 14, 2022
ResumeUBS resumes coverage at Buy, price target $47

Questions about UBS and RPRX

What is UBS's price target for RPRX?: UBS's latest stated price target for Royalty Pharma plc (RPRX) is $49, from its action on Jan 30, 2026.
What is UBS's rating on RPRX?: UBS rates RPRX Buy, a bullish rating, as of Jan 30, 2026.
When did UBS last change its view on RPRX?: On Jan 30, 2026, UBS upgrades to Buy from Neutral, price target $49.

More RPRX rating histories

Morgan Stanley3

All UBS ratings RPRX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.